Gammadelta T cells in cancer immunotherapy: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Editat de Ilan Bank, Dieter Kabelitz, Zhinan Yinen Limba Engleză Hardback – 31 iul 2024
Gammadelta T cells in Cancer Immunotherapy answers the growing interest in the scientific and medical community in general immunotherapy and familiarizes end users with the basic biology of gammadelta T cells, the pre-clinical studies implying their utility in immunotherapy, and with the studies of clinical applications of different forms of gammadelta T cell immunotherapeutic. modalities. Contents will help both basic scientists and clinicians understand how to overcome hurdles inherent to current forms of CAR T cell immunotherapy
- Provides a baseline introduction to the field of gamma delta immunotherapy
- Gives a broad overview of the progress in the field of gammadelta immunotherapy using concrete examples
- Each chapter describes an approach to a specific model of gammadelta immunotherapy
- Edited by Ilan Bank, author of the first paper describing the discovery of a novel type of human thymocyte in forming the basis of recognition of the second T cell receptor (gammadelta) and the subsets of T cells expressing these receptors, known now as gammadelta T cells
Preț: 776.23 lei
Preț vechi: 853.00 lei
-9% Nou
Puncte Express: 1164
Preț estimativ în valută:
148.57€ • 154.85$ • 123.68£
148.57€ • 154.85$ • 123.68£
Carte nepublicată încă
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443218798
ISBN-10: 044321879X
Pagini: 216
Dimensiuni: 191 x 234 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
ISBN-10: 044321879X
Pagini: 216
Dimensiuni: 191 x 234 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Cuprins
Chapter 1 The rationale for use of gd T cells in immunotherapy.
Chapter 2 Tissue derived gammadelta T cells as vehicles for cancer immunotherapy
Chapter 3 DOT-1 gammadelta T cell immunotherapeutic strategies. 4
Chapter 4 Allogeneic Vg9Vd2 T cells treatment for solid tumors.
Chapter 5 Gammadelta T cell receptor therapeutic reagents; mechanisms and applications
Chapter 6 Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens.
Chapter 7 . Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme
Chapter 8 Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma
Chapter 9 Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapy
Chapter 10 Pro tumoral gammadelta T cells and their implication for immunotherapy.
Chapter 11 Overcoming hurdles of gammadelta T cell immunotherapeutics
Chapter 12 Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.
Chapter 13 Summary and conclusions
Chapter 2 Tissue derived gammadelta T cells as vehicles for cancer immunotherapy
Chapter 3 DOT-1 gammadelta T cell immunotherapeutic strategies. 4
Chapter 4 Allogeneic Vg9Vd2 T cells treatment for solid tumors.
Chapter 5 Gammadelta T cell receptor therapeutic reagents; mechanisms and applications
Chapter 6 Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens.
Chapter 7 . Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme
Chapter 8 Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma
Chapter 9 Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapy
Chapter 10 Pro tumoral gammadelta T cells and their implication for immunotherapy.
Chapter 11 Overcoming hurdles of gammadelta T cell immunotherapeutics
Chapter 12 Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.
Chapter 13 Summary and conclusions